Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis — Stella

Home/Allergic Conjunctivitis/

View on ClinicalTrials.gov

Recruiting

Back to Allergic Conjunctivitis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Telios Investigative Site, Memphis, Tennessee

Key details

Phase

Safety & dosing

Sponsor

Telios Pharma, Inc.

Enrollment target

~66 participants

Started

October 2024

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.